NORTH CHICAGO - AbbVie (NYSE: ABBV) announced it is presenting 15 abstracts at the 2024 Digestive Disease Week (DDW) Annual Meeting, being held May 18-21 in Washington, D.C., and virtually.
'AbbVie is presenting research at DDW that evaluated rapid symptom relief and visible improvement in the GI tract across our portfolio,' said Andrew Anisfeld, Ph.D., vice president, global medical affairs, Immunology, AbbVie. 'Advancing the standard of care for IBD patients helps doctors address acute needs, as well as long-term care goals, in a way that can be felt by the patient and measured by their health care team.'
As a leader in gastroenterology, AbbVie is identifying opportunities, driving discoveries, and advancing science to enhance the understanding of IBD. Recognizing that every patient is different, AbbVie has taken bold steps to help shape the IBD landscape, building a diverse portfolio of marketed and investigational products, sharing new evidence that further builds upon our strong scientific foundation and helping elevate the standards of care for people living with IBD.
The research presented at DDW will encompass risankizumab (SKYRIZI) and upadacitinib (RINVOQ) across IBD. Notable data presentations will include: Risankizumab vs. Ustekinumab in Crohn's Disease (SEQUENCE Trial): Compared the efficacy of risankizumab and ustekinumab in achieving STRIDE-II recommended short- and long-term treatment goals of symptomatic, endoscopic, and biomarker improvements in patients with moderate-to-severe Crohn's disease.
Risankizumab in Ulcerative Colitis (COMMAND Study): Evaluated achievement of corticosteroid-free clinical, endoscopic, and histologic outcomes in patients with moderately to severely active ulcerative colitis treated with risankizumab.
Risankizumab Maintenance Therapy in Ulcerative Colitis (COMMAND Study): Investigated the efficacy and safety of risankizumab maintenance therapy in patients with moderately to severely active ulcerative colitis.
Upadacitinib Therapy in Ulcerative Colitis: Explored corticosteroid-free remission over two years of upadacitinib therapy in patients with moderately to severely active ulcerative colitis.
Effect of Upadacitinib on Lipid Profiles in Inflammatory Bowel Disease: Analyzed the impact of upadacitinib on lipid profiles in patients with inflammatory bowel disease, pooling data from Phase 3 induction and maintenance studies in patients with moderately to severely active Crohn's disease or ulcerative colitis.
About Inflammatory Bowel Disease (IBD)
Inflammatory bowel disease (IBD) is a group of diseases characterized by chronic inflammation of the gastrointestinal (GI) tract. Crohn's disease (CD) and ulcerative colitis (UC) are the most common forms of IBD. In both CD and UC, the immune system causes inflammation and damage to the mucosa - or lining - of the gut.8,9,10 Specifically, CD manifests as inflammation within the GI tract, most commonly in the area between the small intestine (ileum) and the colon, causing persistent diarrhea and abdominal pain.8,11 UC is a chronic, idiopathic, immune-mediated IBD of the large intestine that causes continuous mucosal inflammation extending, to a variable extent, from the rectum to the more proximal colon.10,12 The hallmark signs and symptoms of UC include rectal bleeding, abdominal pain, bloody diarrhea, tenesmus (a sense of pressure), urgency and fecal incontinence.10,12 CD and UC are progressive diseases, meaning they get worse over time and may lead to life-threatening complications or surgery.13,14 Because the signs and symptoms of CD and UC are unpredictable, they cause a significant burden on people living with the disease-not only physically, but also emotionally and economically.15
About Digestive Disease Week
Digestive Disease Week (DDW) is the largest international gathering of physicians, researchers and academics in the fields of gastroenterology, hepatology, endoscopy and gastrointestinal surgery. Jointly sponsored by the American Association for the Study of Liver Diseases (AASLD), the American Gastroenterological Association (AGA) Institute, the American Society for Gastrointestinal Endoscopy (ASGE) and the Society for Surgery of the Alimentary Tract (SSAT), DDW is an in-person and online meeting from May 18-21, 2024. The meeting showcases more than 3,100 abstracts and hundreds of lectures on the latest advances in GI research, medicine and technology.
About AbbVie in Gastroenterology
With a robust clinical trial program, AbbVie is committed to cutting-edge research to drive exciting developments in inflammatory bowel diseases (IBD), like ulcerative colitis and Crohn's disease. By innovating, learning and adapting, AbbVie aspires to eliminate the burden of IBD and make a positive long-term impact on the lives of people with IBD.
About AbbVie
AbbVie's mission is to discover and deliver innovative medicines that solve serious health issues today and address the medical challenges of tomorrow. We strive to have a remarkable impact on people's lives across several key therapeutic areas immunology, oncology, neuroscience, eye care and products and services in our Allergan Aesthetics portfolio.
Forward-Looking Statements
Some statements in this news release are, or may be considered, forward-looking statements for purposes of the Private Securities Litigation Reform Act of 1995. The words 'believe,' 'expect,' 'anticipate,' 'project' and similar expressions and uses of future or conditional verbs, generally identify forward-looking statements. AbbVie cautions that these forward-looking statements are subject to risks and uncertainties that may cause actual results to differ materially from those expressed or implied in the forward-looking statements. Such risks and uncertainties include, but are not limited to, challenges to intellectual property, competition from other products, difficulties inherent in the research and development process, adverse litigation or government action, and changes to laws and regulations applicable to our industry. Additional information about the economic, competitive, governmental, technological and other factors that may affect AbbVie's operations is set forth in Item 1A, 'Risk Factors,' of AbbVie's 2023 Annual Report on Form 10-K, which has been filed with the Securities and Exchange Commission, as updated by its subsequent Quarterly Reports on Form 10-Q. AbbVie undertakes no obligation, and specifically declines, to release publicly any revisions to forward-looking statements as a result of subsequent events or developments, except as required by law.
Contact:
Shannelle Fowler
Tel: +1 (773) 520-2106
Email: shannelle.fowler@abbvie.com
Liz Shea
Tel: +1 (862) 261-8130
Email: liz.shea@abbvie.com
ABBVIE INC. 
